UNIVERSAL HEALTH SERVICES INC (UHS) stock intrinsic value fair value estimate & owner earnings analysis

Universal Health Services operates hundreds of facilities: acute care hospitals across the U.S. and a large behavioral health network in the U.S. and the U.K. (Cygnet). Revenue reached $17.4 billion in 2025, up from $9.8 billion in 2016, and the share count has fallen from about 98 million to about 60 million through buybacks. WHAT THE EARNINGS REALLY ARE. We measure what is left for owners: operating cash flow, with working-capital swings removed (for example the $699 million repayment of Medicare advances in 2021), less stock compensation, less the capital spending needed to stay in business. We treat nearly all of UHS's capital spending as maintenance because revenue growth has not translated into growth in owner cash. On that basis, owner earnings per share ran $8.00 (2016), $6.65 (2018), $9.94 (2020), $7.56 (2021), $9.65 (2023), $13.21 (2024) and $17.21 (2025). Adding back interest paid, the business generated about $1.07 billion in 2024 and $1.27 billion in 2025 before its lenders. Our starting level is the 2024-2025 average, about $1.17 billion, because those are the two years under the current state Medicaid supplemental-payment regime (net benefit of $556 million in 2023, $963 million in 2024 and $1.339 billion in 2025). Earlier years describe a business with far smaller program income. Roughly three-quarters of that level, about $895 million after tax, comes from these state programs. They are approved year to year, and UHS estimates $1.36 billion of net benefit for 2026. For 2025, owner cash grew about 19% (from $1.07 billion to $1.27 billion); we assume 0% growth for 2026-27 because the first half of 2026 was roughly flat versus the first half of 2025 (operating cash flow less capital spending and stock compensation, with interest added back, was about $429 million versus $436 million) and nothing filed identifies a reason for faster growth. Accounting note: 2025 cash flow absorbed a $318 million receivables build, of which about $145 million related to state programs; we treat it as timing, and could not fully reconcile whether all of it will be collected. THE KEY RISK. The July 2025 federal budget law caps and phases down state-directed payments and provider-tax financing starting with state fiscal 2028. Management estimates this lowers annual net benefit by $432 million to $480 million by 2032, and a January 2026 CMS provider-tax rule adds uncertainty management says it cannot yet quantify. A second item is the Cumberland Hospital (Virginia) litigation: a jury awarded three plaintiffs $60 million compensatory plus $180 million trebled damages (punitive reduced to about $1 million) in September 2024; about 40 more plaintiffs remain, insurance for that year is about $143 million, appeals are pending and another trial was tentatively planned for August 2026. BASE CASE (about $176 per share). Business cash flow of about $1.17 billion holds through 2027, the $346 million after-tax mid-point of the disclosed cut phases in evenly over 2028-2032, and the underlying hospital cash (about $270 million) grows 2% a year to 2030 and 1% to 2035, matching the roughly 2% a year at which total business cash flow grew in 2016-2019 (from $894 million to $947 million); nothing is credited from new hospitals, volume or pricing beyond that, and afterwards the stream is held flat because the hospitals, licences and state programs at reduced grandfathered levels persist. We assume Cumberland costs $300 million after tax over 2027-2029. Business value is about $15.4 billion. It owes about $4.64 billion (below). Outside owners of partly owned hospitals take about $0.23 billion. The difference is about $10.5 billion, or $176 per share on 59.9 million diluted shares. BEAR CASE (about $122). A genuine bad outcome: supplemental payments erode beyond the disclosed estimate, down to roughly the 2023 level (a $473 million after-tax reduction by 2033, versus $346 million in the base case); a labor-cost squeeze like 2021-22, when business cash flow fell about 22-24% from its 2019-20 level, hits 2029-2032 (about $860 million cumulatively); no growth; and Cumberland costs $800 million after tax. Cash flow bottoms near $460 million in 2029, still about twice the interest bill, so the debt is carried. Business value is about $12.2 billion, less debt $4.64 billion and outside owners $0.18 billion, leaving about $7.3 billion, or $122 per share. If the programs disappeared faster than this, the remaining hospital cash (about $270 million) would not support $4.6 billion of debt and equity would be worth little; we judge that beyond a 10th-percentile outcome but not impossible. BULL CASE (about $230). Programs hold at the 2026 estimate plus the $47 million Florida increase pending at CMS, the disclosed cut lands at the low end ($432 million), underlying cash grows 3% a year to 2030 and 1.5% after, and Cumberland costs $100 million after tax. Business value $18.7 billion, less debt $4.64 billion and outside owners $0.28 billion, leaves $13.75 billion, or $230 per share. DEBT. UHS owes about $4.85 billion (June 2026), mostly secured notes: $700 million at 1.65% (due September 2026, which we treat as refinanced at current rates), $500 million at 4.625% (2029), $800 million and $500 million at 2.65% (2030, 2032), $500 million at 5.05% (2034), plus a bank term loan and revolver. Because about $2.3 billion carries coupons below current rates for four to eight years, we value the debt at about $4.64 billion. Cash is only $139 million and is treated as needed for operations. Operating leases are excluded because their cost is already in cash flow. The nearest maturities are manageable relative to $1+ billion of annual business cash flow. HOW WE TRIED TO BREAK IT. The central assumption is that program income stays near current levels through 2027. The 10-K's own 2026 estimate ($1.362 billion vs $1.339 billion in 2025), the grandfathering of existing programs until 2028, and flat first-half 2026 results support it; no filed fact points to an earlier cut. Estimates before this one used a different method and are not comparable; since the last review, first-half 2026 results were flat, the share count fell further, and we now quantify the Cumberland exposure in every case. MARGIN-OF-SAFETY PRICE: $80. We are fairly sure of the 2024-25 cash level because it is audited, but not of its durability: about three-quarters comes from state programs approved annually and subject to a statutory phase-down. The worst plausible outcome is programs shrinking faster than disclosed together with a large Cumberland judgment. The structure would survive a bear-style version of that (secured notes laddered to 2034, interest covered about twice by even the bear cash flow, $7 billion of hospital property) but not a near-total loss of program income. If we are wrong about program durability or Cumberland, the shares are worth roughly $100-120 in the bear case and could approach zero in the tail. The price assumes a five-year holding period; UHS pays a small dividend and has retired about 40% of its shares since 2016. From $80, the base case implies about 23% a year over five years and the bear case about 15% a year, which is why the margin-of-safety price is set here despite a base value well above it.